Cargando…
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
BACKGROUND: Systemic sclerosis (SSc)-overlap syndromes are a very heterogeneous and remarkable subgroup of SSc-patients, who present at least two connective tissue diseases (CTD) at the same time, usually with a specific autoantibody status. OBJECTIVES: To determine whether patients, classified as o...
Autores principales: | Moinzadeh, Pia, Aberer, Elisabeth, Ahmadi-Simab, Keihan, Blank, Norbert, Distler, Joerg H W, Fierlbeck, Gerhard, Genth, Ekkehard, Guenther, Claudia, Hein, Ruediger, Henes, Joerg, Herich, Lena, Herrgott, Ilka, Koetter, Ina, Kreuter, Alexander, Krieg, Thomas, Kuhr, Kathrin, Lorenz, Hanns-Martin, Meier, Florian, Melchers, Inga, Mensing, Hartwig, Mueller-Ladner, Ulf, Pfeiffer, Christiane, Riemekasten, Gabriela, Sárdy, Miklós, Schmalzing, Marc, Sunderkoetter, Cord, Susok, Laura, Tarner, Ingo H, Vaith, Peter, Worm, Margitta, Wozel, Gottfried, Zeidler, Gabriele, Hunzelmann, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392314/ https://www.ncbi.nlm.nih.gov/pubmed/24389298 http://dx.doi.org/10.1136/annrheumdis-2013-204487 |
Ejemplares similares
-
Older age onset of systemic sclerosis – accelerated disease progression in all disease subsets
por: Moinzadeh, Pia, et al.
Publicado: (2020) -
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy
por: Hunzelmann, Nicolas, et al.
Publicado: (2009) -
5HT(2A )polymorphism His452Tyr in a German Caucasian systemic sclerosis population
por: Kirsten, Holger, et al.
Publicado: (2009) -
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
por: Kreuter, Michael, et al.
Publicado: (2023) -
Versorgungsrealität der stationären vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsstörungen bei systemischer Sklerose in Deutschland
por: Juche, A., et al.
Publicado: (2020)